The average one-year price target for TRACON Pharmaceuticals (NASDAQ:TCON) has been revised to 6.63 / share. This is an increase of 21.88% from the prior estimate of 5.44 dated October 4, 2023. The ...
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...
Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022 “The ENVASARC trial ...
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of ...
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...
TRACON Pharmaceuticals TCON shares are trading lower Thursday morning after the company released the results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC ...
Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. [Operator Instructions]. During today's call, we will be making ...
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback